Literature DB >> 31204143

Concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibody with reducing body myopathy: Possible double trouble.

Jantima Tanboon1, Oranee Sanmaneechai2, Sirirat Charuvanij3, Tumtip Sangruchi4, Angeles S Galindo-Feria5, Ingrid E Lundberg5, Yuko Ohnuki6, Takashi Shiina7, Shigeaki Suzuki8, Ichizo Nishino9.   

Abstract

Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy is less common in children but has been associated with more favorable prognosis than adult patients after immunotherapies. We report anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody positivity in a 6-year-old boy with progressive muscle weakness, scoliosis, spinal rigidity, multiple joint contractures, mild left ventricular hypertrophy, and elevated serum creatine kinase. In contrast to most of previously reported pediatric anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy, he showed little response to immunotherapies. Muscle biopsy contained changes suggestive of myofiber necrosis and regeneration and reducing bodies. The diagnosis of reducing body myopathy was later confirmed by reported c.368A>G (p.His123Arg) mutation in the FHL1 gene. Although the level of association between these two conditions is still inconclusive, this is the first report of concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody with reducing body myopathy emphasizing the possibility of co-occurrence of immune mediated necrotizing myopathy and muscular dystrophy and importance of comprehensive diagnostic investigations in unusual cases.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3-hydroxy-3-methylglutaryl-coenzyme A reductase; FHL1; HMGCR; IMNM; Immune mediated necrotizing myopathy; Reducing body myopathy

Year:  2019        PMID: 31204143     DOI: 10.1016/j.nmd.2019.05.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  2 in total

1.  Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort.

Authors:  Hongxia Yang; Xiaolan Tian; Lining Zhang; Wenli Li; Qingyan Liu; Wei Jiang; Qinglin Peng; Guochun Wang; Xin Lu
Journal:  BMC Musculoskelet Disord       Date:  2022-05-06       Impact factor: 2.562

2.  Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort.

Authors:  Angeles S Galindo-Feria; Begum Horuluoglu; Jessica Day; Catia Fernandes-Cerqueira; Edvard Wigren; Susanne Gräslund; Susanna Proudman; Ingrid E Lundberg; Vidya Limaye
Journal:  Rheumatology (Oxford)       Date:  2022-10-06       Impact factor: 7.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.